The medicine is usually available in big pharmacies around four kilometres away from her home in Mysuru, but the technologist in her 30s wanted to save time on travel.
| Quantity | Rate/Share |
|---|---|
| 100 - 1000 | 10.00 |
| P/E | -10.52 | P/S | 9.06 | P/B | 0.95 |
|---|---|---|---|---|---|
| Industry PE | 0 | Face Value | 1 | Book Value | 9.6 |
| Market Cap | 13383.7 Cr | Dividend | 0 | Dividend Yield | 0 % |
Corporate Action of Pharmeasy Unlisted Share Prices
| Financial Year | Particulars | Record Date | Ratio/Rates/Amount | Remarks |
|---|---|---|---|---|
| 2024-25 | RIGHTS | 15-Apr-2024 | 1:17 | Pharmeasy has issued CCPS B, which is the right issue at 1:17 @ 96.80. Shareholders Will get 20 Equity shares in against of 1 CCPS Shares. |
| 2023-24 | RIGHTS | 11-Aug-2023 | 1:17 | Pharmeasy is going to issue CCPS B, which is the right issue at 1:17 @ 96.80. Shareholders Will get 20 Equity shares in against of 1 CCPS Shares. |
| 2021-22 | STOCK SPLIT | 29-Oct-2021 | 10:01 | Pharmeasy has announced stock split from face value Rs 10 to Rs 1 per share. |
About of Pharmeasy
Investors should sell equity shares and buy CCPS for making a gain of 10% in the process.API Holdings Limited (AHL), as per its annual report, the company was engaged in the business of providing diversified delivery/logistics services which includes pick-up and delivery of pharmaceutical and nutraceutical products, to its group entities, as well as third parties, being wholesalers, retailers and marketplace entities across the healthcare ecosystem. Further, during the year under review, the company had transferred its businesses of wholesale and distribution of drugs (including pharmaceutical products, medical devices, and OTC drugs) and ownership of technology and intellectual property for developing e-commerce platforms including marketplaces for facilitating the sale of pharmaceutical, medical devices, and OTC drugs to its wholly-owned subsidiaries through a slump sale on a going concern basis.
Overview of Pharmeasy
PharmEasy is a consumer healthcare “super app” that provides consumers with on-demand, home delivered access to a wide range of prescription, OTC pharmaceutical, other consumer healthcare products, comprehensive diagnostic test services, and teleconsultations thereby serving their healthcare needs.
API Holdings Ltd aka Pharmeasy is India’s largest digital healthcare platform (based on GMV of products and services sold for the year ended March 31, 2021), according to RedSeer Report.
Pharmeasy operate an integrated, end-to-end business that aims to provide solutions for the healthcare needs of consumers across the following critical stages -
A. providing digital tools and information on illness and wellness,
B. offering teleconsultation,
C. offering diagnostics and radiology tests, and
D. delivering treatment protocols including products and devices
Product Offerings
- Healthcare
- Personal Care
- Healthcare devices
- Health Food & Drinks
- Accessories & Wearables
- Home Care
Timeline
2015: PharmEasy was founded by Dharmil Sheth and Dhaval Shah in Mumbai, India
2016: Raised $5 million in Series A funding led by Bessemer Venture Partners
2017: Secured $18 million in two rounds of Series B funding from Bessemer Venture Partners
2018: Raised $77.23 million across two Series C funding rounds from Eight Roads Ventures India, F-Prime Capital
2019: Raised $220 million in Series D funding from Temasek Holdings
2020: Merger of Medlife with PharmEasy
2021:
- PharmEasy acquired a 66.1% stake in Thyrocare for ₹4,546 crore ($620 million)
- Acquired a majority stake in healthcare supply chain company Aknamed
- Raised $500 million in Series F funding
- Completed a Pre-IPO round of $354 million
- Received additional private equity funding from VestinWolf Capital Management
- Filed for an initial public offering (IPO) of ₹6,250 crore ($843.46 million)
2022: PharmEasy withdrew its IPO plans and went with rights issue
Management
Siddharth Shah: Co-Founder, Managing Director and Chief Executive Officer
- He holds a bachelor’s degree in computer engineering from the Dwarakadas J. Sanghavi College, Mumbai
- Post graduate diploma in management from the Indian Institute of Management, Ahmedabad
- He was associated with Ascent Health and Wellness Solutions Private Limited as its managing director
Dharmil Sheth: Co-Founder and Whole-time Director
- Bachelor’s degree in electronics engineering from the K.J. Somaiya College of Engineering, University of Mumbai
- Post graduate diploma degree in management (marketing) from the Institute of Management Technology, Ghaziabad.
- He was associated with MakeMyTrip (India) Private Limited as a part of the online products team
- 91Streets Media Technologies Private Limited as director and co-founder.
Dr. Dhaval Shah: Co-Founder
- Post graduate diploma in management from XLRI, Xavier School of Management, Jamshedpur, Jharkhand
- MBBS degree certificate from the Maharashtra University of Health Sciences, Nashik
- McKinsey and Company Inc. as a consultant
- Associated with 91Streets Media Technologies Private Limited as an executive director
Harsh Parekh: Co-Founder and Whole-time Director
- Master’s degree in business administration from the School of Business Management, Narsee Monjee Institute of Management Studies, Mumbai
- Chief Operations Officer of Ascent Health and Wellness Solutions Private Limited
Hardik Dedhia: Co-Founder
- He joined Ascent Health and Wellness Solutions Private Limited
- Bachelor’s degree in electronics and telecommunication engineering from the University of Mumbai, Maharashtra
- Master’s degree in electrical and computer engineering from the Carnegie Mellon University, Pennsylvania
Insights of Pharmeasy
Financial Insight
| Particulars | 31st March, 2023 | 31st March, 2022 |
| Revenue | 6700 | 5781 |
| EBITDA | -1365 | -2300 |
| PBT | -5197 | -3971 |
| PAT | -5212 | -3993 |
Marquee Investors
- Naspers Ventures BV
- Macritchie Investments Pte Ltd
- TP G Growth V SF Markets Pvt Ltd
IPO Updates
API Holdings, the parent company of online pharmacy start-up PharmEasy, on Monday received approval from Sebi to raise Rs 6,250 crore through an initial public offering (IPO).
Pharmeasy was last valued at $5.6 billion (Rs 42,197.79 crore) in a Rs 2,635.22-crore pre-IPO round in October 21.
Balance Sheet of Pharmeasy
Standalone(in ₹ Cr.)
| Category | 31-Mar-2022 | 31-Mar-2021 | 31-Mar-2020 |
|---|---|---|---|
| Equity | 6246.52 | 4023.75 | 309.35 |
| Liabilities | 474.99 | 118.63 | 322.44 |
| Total Equity and Liabilities | 6721.51 | 4142.38 | 631.79 |
| Net Fixed Assets | 331.23 | 1.20 | 56.71 |
| Capital Work-in-progress | 0.00 | 0.00 | 0.35 |
| Other Non current Assets | 6188.89 | 2405.65 | 38.60 |
| Current Assets | 201.39 | 1735.54 | 536.13 |
| Total Assets | 6721.51 | 4142.38 | 631.79 |
Consolidated
| category | 31-Mar-2023 | 31-Mar-2022 | 31-Mar-2021 | 31-Mar-2020 |
|---|---|---|---|---|
| Equity | 6115.69 | 7022.48 | 3581.18 | 246.24 |
| Liabilities | 5226.97 | 4375.86 | 1303.40 | 326.23 |
| Total Equity and Liabilities | 11342.66 | 11398.34 | 4884.58 | 572.47 |
| Net Fixed Assets | 8186.98 | 8320.93 | 3415.23 | 63.60 |
| Capital Work-in-progress | 5.86 | 6.96 | 0.25 | 0.35 |
| Other Non current Assets | 580.95 | 568.24 | 150.98 | 32.83 |
| Current Assets | 2568.87 | 2502.21 | 1318.11 | 475.69 |
| Total Assets | 11342.66 | 11398.34 | 4884.58 | 572.47 |
Profit and Loss of Pharmeasy
Standalone(in ₹ Cr.)
| Category | 31-Mar-2022 | 31-Mar-2021 | 31-Mar-2020 |
|---|---|---|---|
| Net Revenue | 169.74 | 38.23 | 28.45 |
| Total Operating Cost | 1036.52 | 120.58 | 9.16 |
| Operating Profit (EBITDA) | -866.78 | -82.36 | 19.29 |
| Other Income | 177.10 | 24.15 | 0.15 |
| Depreciation and Amortization Expense | 3.52 | 0.23 | 0.13 |
| Profit Before Interest and Taxes | -693.20 | -58.43 | 19.31 |
| Finance Costs | 46.86 | 2.97 | 0.15 |
| Profit Before Tax and Exceptional Items Before Tax | -740.06 | -61.40 | 19.16 |
| Exceptional Items Before Tax | 4340.96 | 0.00 | 0.00 |
| Profit Before Tax | -5081.02 | -61.40 | 19.16 |
| Income Tax | 0.00 | 0.08 | 0.02 |
| Profit for the Period from Continuing Operations | -5081.02 | -61.48 | 19.14 |
| Profit from Discontinuing Operations After Tax | 0.00 | -166.36 | -317.88 |
| Profit for the Period | -5081.02 | -227.84 | -298.74 |
Consolidated(in ₹ Cr.)
| Category | 31-Mar-2023 | 31-Mar-2022 | 31-Mar-2021 | 31-Mar-2020 |
|---|---|---|---|---|
| Net Revenue | 6705.12 | 5728.82 | 2335.27 | 667.54 |
| Total Operating Cost | 8275.26 | 8074.55 | 2904.60 | 1053.75 |
| Operating Profit (EBITDA) | -1570.14 | -2345.73 | -569.33 | -386.21 |
| Other Income | 47.84 | 52.18 | 25.39 | 69.91 |
| Depreciation and Amortization Expense | 239.73 | 158.78 | 32.90 | 18.77 |
| Profit Before Interest and Taxes | -1762.03 | -2452.33 | -576.84 | -335.07 |
| Finance Costs | 520.28 | 258.20 | 43.43 | 11.89 |
| Profit Before Tax and Exceptional Items Before Tax | -2282.31 | -2710.53 | -620.27 | -346.96 |
| Exceptional Items Before Tax | 0.86 | -1260.19 | 0.00 | 0.00 |
| Profit Before Tax | -2281.45 | -3970.72 | -620.27 | -346.96 |
| Income Tax | -4.57 | 21.77 | 21.07 | -11.68 |
| Profit for the Period from Continuing Operations | -2276.88 | -3992.49 | -641.34 | -335.28 |
| Minority interest and profit from associates and joint ventures | 0.00 | 0.00 | 5.15 | 0.06 |
| Profit for the Period | -2276.88 | -3992.49 | -636.19 | -335.22 |
Management of Pharmeasy
HARSH SHAILESH PAREKH - Additional Director
DHAVAL RAJESH SHAH - Additional Director
FAQs of Pharmeasy
-
What Is The Lock-In Period Of Most Unlisted Shares?
The lock-in period of unlisted shares depends on the category of investors
For retail Investors, HNIs, or Body Corporates, the lock-in period is 6 months from the date of the listing of Bira91 (B9 Beverages Ltd.)
For Venture Capital Funds or Foreign Venture Capital Investors, there is a lock-in period of 6 months from the date of acquisition of Bira91 (B9 Beverages Ltd.)
For AIF-II (Alternative Investment Funds - Category II), there is no lock-in period
This regulation was brought by SEBI in August 2021. The purpose of the regulation change of lower lock-in period, was primarily to promote greater participation and investments before the IPO listing. Hence, PMS< retail investors, institutions can enjoy better liquidity.
-
How Is The Price Calculated?
Unlisted share price determination is also driven by same values – Fundamental values and current demand and supply.
-
What Is The Minimum Investment Ticket Size For Buying Unlisted Shares?
We generally address ticket size of Rs 25000 (closest round off).
Press of Pharmeasy
5th Jun 2024
PharmEasy Rights Issue: Epharmacy Raises INR 1,804 Cr At A 90% Valuation Cut
Barely a month after the Competition Commission of India (CCI) greenlit PharmEasy’s INR 3,500 Cr rights issue, the digital pharmacy has raised INR 1,804 Cr ($216.2 Mn) in a down round led by the family office of Manipal Group chairman Ranjan Pai.
5th Jun 2024
CCI clears Ranjan Pai’s investment in PharmEasy
The Competition Commission of India (CCI) has cleared Manipal group chief Ranjan Pais investment in online pharmacy PharmEasy, according to the latest filing by the antitrust regulator. An additional investment from 360 One (formerly IIFL) in PharmEasy has also been cleared.
Company Information of Pharmeasy
ISIN: INE0DJ201029
Address: 902, 9th Floor, Raheja Plaza 1, B-Wing, Opposite R-City Mall, L.B.S Marg, Ghatkopar (W) MUMBAI MAHARASHTRA 400086
Email: legal@apiholdings.in
Phone Number: +91-22-62556255
Date of Incorporation: 31-Mar-2019
Date of Last AGM: 01-Oct-2021
Data as Date: 31-Mar-2022
Source of Data: MCA, Toffler, Probe42